| AGIOS PHARMACEUT. DL-,001 |
| USA |
| Gesundheit |
| US00847X1046 / A1W2RM |
| 8AP (Frankfurt) / AGIO (NASDAQ) |
| FRA:8AP, ETR:8AP, 8AP:GR, NASDAQ:AGIO |
| - |
| https://www.agios.com/ |
|
Agios Pharmaceuticals Inc. is a biopharmaceutical company specializing in cellular metabolism to develop differentiated medicines for rare diseases, with a particular emphasis on classical hematology. The company focuses on creating potentially trans..
>Volltext.. |
| 2012.97 Mio. EUR |
| 1405.88 Mio. EUR |
| 57.74 Mio. EUR |
| -411.09 Mio. EUR |
| -369.42 Mio. EUR |
| -6.34 EUR |
| 31.25 Mio. EUR |
| 99.31 Mio. EUR |
| -332.54 Mio. EUR |
| 12.53 |
| 66.99% |
| -159.42% |
| - |
| - |
| - |
| AGIOS |
| 21.07.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|